How should mineralocorticoid receptor antagonist therapy (e.g., spironolactone or eplerenone) be initiated, titrated, and monitored in a patient with confirmed primary aldosteronism and bilateral adrenal hyperplasia or who is not a surgical candidate?

MRA Therapy for Primary Aldosteronism: Initiation, Titration, and Monitoring

For patients with bilateral primary aldosteronism or those not suitable for surgery, initiate spironolactone at 12.5-25 mg daily (or 25-50 mg daily if severe hypokalemia is present), titrate every 8-12 weeks by 25-50 mg increments targeting blood pressure control and normokalemia, with monitoring of electrolytes, renal function, and renin at 2-3 months after each dose adjustment. 1

Drug Selection

Spironolactone is the first-line MRA for primary aldosteronism 2. The FDA-approved dosing for primary hyperaldosteronism is 100-400 mg daily 3. However, the most recent 2025 Endocrine Society guideline provides more nuanced, lower starting doses based on patient characteristics 1.

Eplerenone is an alternative when spironolactone causes intolerable side effects, particularly gynecomastia in men. Eplerenone requires 2-3 times higher doses than spironolactone (typically 50-100 mg twice daily initially, maximum 200-300 mg/day in divided doses) to achieve similar efficacy 2. The FDA approves eplerenone for hypertension but not specifically for primary aldosteronism 4.

Initiation Protocol

Starting Doses

• Standard patients: Spironolactone 12.5-25 mg daily OR eplerenone 25 mg once or twice daily 1
• Severe PA with profound hypokalemia: Spironolactone 50 mg daily OR eplerenone 50 mg twice daily 1
• Elderly or reduced kidney function: Spironolactone 12.5 mg daily 2
• Medically complex patients or those on ACE inhibitors/ARBs: Start low and monitor carefully for hyperkalemia 1

Critical First Steps

Discontinue potassium supplements on days 2-4 of MRA initiation in most patients, as normokalemia typically occurs within 3-5 days even with lower-dose MRAs 1. Only the most severe hypokalemic cases require ongoing supplementation, which necessitates frequent potassium monitoring.

Implement strict dietary sodium restriction (<85.5 mmol/day or <5 g/day salt) 1. This is critical—high-salt diets are the most common reason for apparent MRA nonresponse.

Titration Strategy

The Algorithm

The 2025 guideline emphasizes a multi-step, iterative process 1:

1. Primary goal: Blood pressure control (<140/90 mmHg)
2. Secondary goal: Normokalemia
3. Biochemical marker: Renin de-suppression (indicates adequate MR blockade)

Dose Adjustments

• Timing: Increase doses at 8-12 week intervals 1. Full drug effect may take up to 3 months in severe PA.
• Spironolactone: Increase by 25-50 mg increments 1
• Eplerenone: Increase by 25-100 mg increments 1
• Target doses: Most patients achieve renin de-suppression with spironolactone 50-100 mg/day (higher than doses used for resistant hypertension) 1

Decision Points

After each dose adjustment:

• If BP controlled on MRA monotherapy with de-suppressed renin → maintain current dose (insufficient evidence to increase MRA further based on low renin alone) 1
• If BP controlled but renin still suppressed → continue titrating MRA 1
• If renin de-suppressed but BP not controlled → add or uptitrate non-MRA antihypertensives (ACE inhibitors, ARBs, calcium channel blockers) 1, 2
• Consider off-titration of other antihypertensives when possible during MRA uptitration 1

Monitoring Protocol

Initial Phase (First 2-3 Months)

Measure at 2-3 months after starting or adjusting MRA 1:

• Serum potassium
• Serum creatinine/eGFR
• Plasma renin activity or direct renin concentration

More frequent monitoring is needed for:

• Prior severe hypokalemia
• Renal impairment (eGFR 30-50 mL/min/1.73m²)
• Concurrent ACE inhibitor or ARB use

Ongoing Monitoring

After dose optimization: Annual blood pressure monitoring, potassium, and kidney function 1

More frequent monitoring for patients with chronic kidney disease or other comorbidities 1

Critical Safety Considerations

Renal Function Changes

Expect GFR to decrease initially when starting or titrating MRA 1. This typically occurs over days to weeks and represents a marker of treatment efficacy, not adverse effect. The natural history shows eventual long-term stability with a renal-sparing effect 1.

If renal function progressively declines: Consider nephrology referral and discontinue ACE inhibitors/ARBs 1

Contraindications and Cautions

• Avoid MRAs when eGFR <30 mL/min/1.73m² 2, 3, 4
• Use with extreme caution in stage 3 CKD (eGFR 30-50 mL/min/1.73m²) due to hyperkalemia risk 2
• Never initiate if serum potassium >5.5 mEq/L 4
• Pregnancy: Use alpha-methyldopa instead (spironolactone causes fetal feminization) 2

Managing Side Effects

Gynecomastia (spironolactone-specific):

• Dose-related, appearing at 1-2 months but more commonly after ≥6 months 1
• Occurs in 10% at 25 mg/day, up to 52% at ≥150 mg/day 2
• Management: Reduce to ≤50 mg/day (may resolve in younger males) or switch to eplerenone 1, 2

Hyperkalemia:

• If develops on 25 mg daily spironolactone → reduce to 25 mg every other day 1
• More common with eplerenone due to higher required doses, though clinical trials show similar withdrawal rates 5

Common Pitfalls to Avoid

1. Inadequate dietary sodium restriction: Explicitly instruct patients on salt reduction strategies—this is the most common cause of treatment failure 1
2. Premature dose escalation: Wait full 8-12 weeks between adjustments 1
3. Stopping potassium supplements too late: Most patients should discontinue by day 2-4 1
4. Misinterpreting initial GFR decline as drug toxicity: This is usually therapeutic effect 1
5. Inadequate monitoring frequency: Check labs 2-3 months after each change, not just annually 1